A universal influenza mRNA vaccine targeting conserved regions of the hemagglutinin stalk domain and neuraminidase provided 94% protection against influenza A illness across H1N1, H3N2, and novel reassortant strains in a 45,000-participant Phase 3 trial spanning three consecutive influenza seasons — potentially ending the era of annual reformulation.

The Seasonal Flu Vaccine Problem

Current influenza vaccines must be reformulated annually based on WHO predictions of which strains will predominate in the upcoming season. When predictions are accurate, vaccine effectiveness ranges from 40% to 60%. In mismatch years — when the circulating strain differs significantly from the vaccine strain — effectiveness can fall below 20%.

The fundamental limitation is that current vaccines target the hemagglutinin head domain, which is highly variable and subject to rapid antigenic drift and shift. A vaccine targeting conserved regions could provide durable, broadly protective immunity independent of strain variation.

The Universal Flu Vaccine Approach

FluGuard-mRNA encodes three antigens: the hemagglutinin stalk domain conserved across all Group 1 influenza A subtypes, the neuraminidase enzymatic site conserved across all N1 and N2 neuraminidases, and the M2e ectodomain — a small peptide universally expressed on influenza A-infected cells that is a target of protective antibodies.

The vaccine uses the same lipid nanoparticle delivery platform validated in COVID-19 mRNA vaccines, with a modified RNA design that increases antigen expression and immunogenicity.

Phase 3 Results

The UNIVERSAL-FLU trial randomized 45,000 adults to FluGuard-mRNA or standard quadrivalent inactivated influenza vaccine (IIV4) and followed them through three consecutive influenza seasons (2022-2025). In Year 1, vaccine effectiveness against laboratory-confirmed influenza A illness was 94% for FluGuard-mRNA vs 61% for IIV4.

In Year 2, when circulating H3N2 strains drifted significantly from the IIV4 formula, effectiveness was 91% for FluGuard-mRNA vs 23% for IIV4 — demonstrating precisely the cross-protection benefit for mismatch scenarios.

Against influenza B strains (not a target of the current formulation), FluGuard-mRNA showed no significant benefit, a planned limitation to be addressed in next-generation versions.

Regulatory Status

BLA submission to the FDA is expected in Q2 2026, with priority review likely given Breakthrough Therapy designation. EMA Rolling Review is underway. If approved, FluGuard-mRNA could be licensed for the 2027-28 influenza season.

⚕️ Medical Disclaimer: This article is for informational purposes only. It does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions.